Showing 1 to 8 of 8 results
DLBCL Treatment: High Relapse Rates, Promising Immunotherapies
Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma, affects around 3,000 people annually in Spain; while 60-70% of patients are cured with initial chemotherapy, 40% relapse, necessitating innovative treatments like CAR-T cell therapy, which offers a 40% cure rate but...
DLBCL Treatment: High Relapse Rates, Promising Immunotherapies
Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma, affects around 3,000 people annually in Spain; while 60-70% of patients are cured with initial chemotherapy, 40% relapse, necessitating innovative treatments like CAR-T cell therapy, which offers a 40% cure rate but...
Progress
52% Bias Score
World-First CAR-T Therapy Success in Treating Anti-MD5 Dermatomyositis
Hospital Universitario La Paz successfully treated a child with anti-MD5 dermatomyositis, a rare autoimmune disease with high mortality, using CAR-T cell therapy (ARI-0001) for the first time globally, resulting in remission after one year and highlighting the therapy's potential for treating other ...
World-First CAR-T Therapy Success in Treating Anti-MD5 Dermatomyositis
Hospital Universitario La Paz successfully treated a child with anti-MD5 dermatomyositis, a rare autoimmune disease with high mortality, using CAR-T cell therapy (ARI-0001) for the first time globally, resulting in remission after one year and highlighting the therapy's potential for treating other ...
Progress
44% Bias Score
18-Year Cancer Remission Achieved with First-Generation CAR-T Therapy in Neuroblastoma Patient
An 18-year cancer remission in a neuroblastoma patient treated with first-generation CAR-T cell therapy at age four has been reported, exceeding previous remission records for both hematological and solid cancers, highlighting the therapy's potential for broader applications.
18-Year Cancer Remission Achieved with First-Generation CAR-T Therapy in Neuroblastoma Patient
An 18-year cancer remission in a neuroblastoma patient treated with first-generation CAR-T cell therapy at age four has been reported, exceeding previous remission records for both hematological and solid cancers, highlighting the therapy's potential for broader applications.
Progress
44% Bias Score
Russian Boy's Cancer Fight Highlights Sanctions' Impact on Healthcare
Misha, a 10-year-old boy from Russia, battles T-cell lymphoblastic lymphoma; after exhausting domestic treatment options, his family seeks expensive CAR-T cell therapy in China, facing a financial shortfall of 2.5 million rubles despite significant fundraising efforts.
Russian Boy's Cancer Fight Highlights Sanctions' Impact on Healthcare
Misha, a 10-year-old boy from Russia, battles T-cell lymphoblastic lymphoma; after exhausting domestic treatment options, his family seeks expensive CAR-T cell therapy in China, facing a financial shortfall of 2.5 million rubles despite significant fundraising efforts.
Progress
56% Bias Score
EMA Conditionally Approves Ocatazil for Relapsed/Refractory ALL
The European Medicines Agency (EMA) conditionally approved Ocatazil, a CAR-T cell therapy, for adults (≥26) with relapsed or refractory acute lymphoblastic leukemia (ALL), based on a Phase 2 trial showing 64% complete response rate (n=113) with a median duration of 14 months; however, serious side e...
EMA Conditionally Approves Ocatazil for Relapsed/Refractory ALL
The European Medicines Agency (EMA) conditionally approved Ocatazil, a CAR-T cell therapy, for adults (≥26) with relapsed or refractory acute lymphoblastic leukemia (ALL), based on a Phase 2 trial showing 64% complete response rate (n=113) with a median duration of 14 months; however, serious side e...
Progress
40% Bias Score
Unexpected Cancer Transformation During Treatment Leads to CAR-T Therapy
An Israeli man with lymphoma experienced severe pain requiring a ureteral stent; a delayed, non-sedated procedure led to further complications, revealing a new cancerous mass and necessitating CAR-T therapy.
Unexpected Cancer Transformation During Treatment Leads to CAR-T Therapy
An Israeli man with lymphoma experienced severe pain requiring a ureteral stent; a delayed, non-sedated procedure led to further complications, revealing a new cancerous mass and necessitating CAR-T therapy.
Progress
36% Bias Score
CAR T-cell Therapy for Breast Cancer: Early Trials Show Promise, but Challenges Remain
Currently, 16 active phase I/II clinical trials are investigating CAR T-cell therapy for various solid tumors, including breast cancer, primarily in the US, focusing on safety and feasibility; results are preliminary, showing some encouraging but limited data, with no phase III trials yet.
CAR T-cell Therapy for Breast Cancer: Early Trials Show Promise, but Challenges Remain
Currently, 16 active phase I/II clinical trials are investigating CAR T-cell therapy for various solid tumors, including breast cancer, primarily in the US, focusing on safety and feasibility; results are preliminary, showing some encouraging but limited data, with no phase III trials yet.
Progress
40% Bias Score
New CAR-T Therapy Shows Promise Against HER2-Positive Cancers
Spanish researchers develop a promising new CAR-T therapy for HER2-driven cancers showing complete and lasting antitumoral response in preclinical trials.
New CAR-T Therapy Shows Promise Against HER2-Positive Cancers
Spanish researchers develop a promising new CAR-T therapy for HER2-driven cancers showing complete and lasting antitumoral response in preclinical trials.
Progress
24% Bias Score
Showing 1 to 8 of 8 results